12/2/2020, 9:43 PM (Source: TeleTrader)
more TeleTrader news

Astrazeneca's vaccine not likely to get FDA nod yet - adviser

The Food and Drug Administration probably won't grant approval to AstraZeneca plc's coronavirus vaccine before the end of the trial in the United States, chief scientific adviser to Operation Warp Speed Moncef Slaoui said on Wednesday.

AstraZeneca's results from two studies conducted in the United Kingdom and Brazil previously showed the vaccine having between 62% and 90% efficacy rate.

"Frankly, unless there is a very clear explanation based on facts and data for what's behind those two numbers, it’s very likely that that package would not be sufficient for an approval," Slaoui stated, adding that the regulator will "of course make their own decision."

Breaking the News / MD